131,045 members

Skip to content. | Skip to navigation

News

New migraine drug not cost-effective says NICE

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

New migraine drug not cost-effective says NICE

A new drug for preventing migraine is not a good use of NHS resources, according to draft guidance from NICE.

The guidance looks at erenumab (also called Aimovig and made by Novartis) for preventing chronic and episodic migraine in adults who have four or more episodes of migraine a month.